Free Trial

XOMA Royalty (XOMA) Competitors

XOMA Royalty logo
$26.17 -0.79 (-2.93%)
As of 07/7/2025 04:00 PM Eastern

XOMA vs. INVA, DVAX, MNKD, OPK, NVAX, GERN, RGLS, MYGN, ZBIO, and RIGL

Should you be buying XOMA Royalty stock or one of its competitors? The main competitors of XOMA Royalty include Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Novavax (NVAX), Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), Zenas BioPharma (ZBIO), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "biotechnology" industry.

XOMA Royalty vs. Its Competitors

Innoviva (NASDAQ:INVA) and XOMA Royalty (NASDAQ:XOMA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

In the previous week, XOMA Royalty had 1 more articles in the media than Innoviva. MarketBeat recorded 1 mentions for XOMA Royalty and 0 mentions for Innoviva. XOMA Royalty's average media sentiment score of 0.74 beat Innoviva's score of 0.00 indicating that XOMA Royalty is being referred to more favorably in the news media.

Company Overall Sentiment
Innoviva Neutral
XOMA Royalty Positive

Innoviva has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, XOMA Royalty has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Innoviva presently has a consensus target price of $55.00, suggesting a potential upside of 190.85%. XOMA Royalty has a consensus target price of $69.50, suggesting a potential upside of 165.57%. Given Innoviva's higher possible upside, analysts clearly believe Innoviva is more favorable than XOMA Royalty.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innoviva
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
XOMA Royalty
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

99.1% of Innoviva shares are held by institutional investors. Comparatively, 95.9% of XOMA Royalty shares are held by institutional investors. 2.3% of Innoviva shares are held by insiders. Comparatively, 9.1% of XOMA Royalty shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Innoviva has higher revenue and earnings than XOMA Royalty. XOMA Royalty is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innoviva$358.71M3.31$23.39M-$1.01-18.72
XOMA Royalty$13.05M24.00-$13.82M-$1.15-22.76

XOMA Royalty has a net margin of -13.04% compared to Innoviva's net margin of -16.15%. Innoviva's return on equity of 15.77% beat XOMA Royalty's return on equity.

Company Net Margins Return on Equity Return on Assets
Innoviva-16.15% 15.77% 8.41%
XOMA Royalty -13.04%-12.43%-4.85%

Summary

Innoviva beats XOMA Royalty on 8 of the 14 factors compared between the two stocks.

Get XOMA Royalty News Delivered to You Automatically

Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XOMA vs. The Competition

MetricXOMA RoyaltyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$322.63M$2.91B$5.52B$9.02B
Dividend YieldN/A2.44%5.24%4.07%
P/E Ratio-22.7620.4427.2220.04
Price / Sales24.00181.20380.3292.37
Price / CashN/A41.7026.2128.59
Price / Book3.777.397.945.55
Net Income-$13.82M-$55.04M$3.17B$248.49M
7 Day Performance-0.65%2.51%1.81%4.87%
1 Month Performance3.64%-0.21%1.28%6.63%
1 Year Performance6.17%3.41%33.57%20.38%

XOMA Royalty Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XOMA
XOMA Royalty
4.2938 of 5 stars
$26.17
-2.9%
$69.50
+165.6%
+2.1%$322.63M$13.05M-22.7610
INVA
Innoviva
3.8567 of 5 stars
$20.09
+0.7%
$55.00
+173.8%
+15.6%$1.25B$358.71M-19.89100
DVAX
Dynavax Technologies
4.3732 of 5 stars
$9.92
+0.1%
$24.00
+141.9%
-8.4%$1.19B$277.25M-19.08350
MNKD
MannKind
2.5173 of 5 stars
$3.74
-0.5%
$10.33
+176.3%
-31.0%$1.14B$285.50M37.40400Negative News
OPK
OPKO Health
4.2186 of 5 stars
$1.32
flat
$2.75
+108.3%
+6.3%$1.05B$713.10M-18.852,997
NVAX
Novavax
4.4691 of 5 stars
$6.30
-1.1%
$17.00
+169.8%
-44.5%$1.03B$682.16M2.381,990
GERN
Geron
2.8548 of 5 stars
$1.41
-5.4%
$5.06
+259.0%
-69.8%$949.01M$76.99M-6.7170Gap Down
RGLS
Regulus Therapeutics
1.5535 of 5 stars
$8.16
flat
$8.50
+4.2%
N/A$564.92MN/A-11.1830
MYGN
Myriad Genetics
4.1209 of 5 stars
$5.31
+1.1%
$14.38
+170.9%
-78.8%$483.93M$837.60M-4.742,700
ZBIO
Zenas BioPharma
1.1945 of 5 stars
$9.69
+1.1%
$36.67
+278.4%
N/A$400.77M$5M-2.73N/APositive News
RIGL
Rigel Pharmaceuticals
2.3709 of 5 stars
$18.73
-3.9%
$36.40
+94.3%
+142.2%$348.15M$179.28M9.05160

Related Companies and Tools


This page (NASDAQ:XOMA) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners